Screener
Lexicon Pharmaceuticals LXRX Business Segments — Other segment expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 16,059 | 14,127 | 27,446 | 27,736 |
| Sales and marketing | 834 | 1,233 | 1,915 | 3,908 |
| General and administrative | 6,964 | 6,466 | 13,408 | 14,292 |
| Other segment expense (1) | 3,336 | 3,271 | 6,414 | 6,072 |
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 |
| (Loss) income from operations | (26,540) | 3,736 | (27,536) | (21,943) |
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — other segment expense?
- Lexicon Pharmaceuticals (LXRX) reported business segments — other segment expense of $3.34M in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — other segment expense changed year-over-year?
- Lexicon Pharmaceuticals's business segments — other segment expense increased by 2.0% year-over-year, from $3.27M to $3.34M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — other segment expense?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — other segment expense has grown at a 1.8% compound annual growth rate (CAGR), from $11.82M to $12.48M.
- What does business segments — other segment expense mean?
- Miscellaneous operating costs associated with the segment that do not fall under standard categories like R&D or sales. This may include restructuring charges, legal settlements, or other non-recurring operational outflows. Tracking this helps investors identify hidden costs that impact the segment's bottom-line performance.
Ask your AI about Lexicon Pharmaceuticals's business segments — other segment expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude